William Osler Health System - Academic Profile

Publications

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam , Johan Vansteenkiste , David Planchard +21 more

Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a compar...

2019 New England Journal of Medicine 2577 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Affiliated Researchers

Henry Jacob Conter

William Osler Health System

Institution Info

Type: healthcare
Country: CA
Publications: 2
Citations: 4,174

External Links

Identifiers

ROR: https://ror.org/03d1xjg58